[go: up one dir, main page]

WO2024134380A1 - Compositions pour dispositifs ophtalmologiques - Google Patents

Compositions pour dispositifs ophtalmologiques Download PDF

Info

Publication number
WO2024134380A1
WO2024134380A1 PCT/IB2023/062625 IB2023062625W WO2024134380A1 WO 2024134380 A1 WO2024134380 A1 WO 2024134380A1 IB 2023062625 W IB2023062625 W IB 2023062625W WO 2024134380 A1 WO2024134380 A1 WO 2024134380A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
kit
product
contact lens
Prior art date
Application number
PCT/IB2023/062625
Other languages
English (en)
Inventor
Frank Neely
Original Assignee
Johnson & Johnson Vision Care, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care, Inc. filed Critical Johnson & Johnson Vision Care, Inc.
Publication of WO2024134380A1 publication Critical patent/WO2024134380A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/086—Container, accessories or devices therefor

Definitions

  • the present invention relates eye care compositions, including contact lens packaging solutions containing at least one phosphate compound and a chelant in an amount effective to inhibit the growth of microorganisms without additional microbial growth inhibiting compounds.
  • compositions of the present invention are also disclosed.
  • BACKGROUND OF THE INVENTION Contact lenses are generally provided to consumers as individually packaged products.
  • the single unit containers which package such contact lenses typically use buffered saline as storage or packaging solutions.
  • Such packaging solutions should provide for, at least in some cases, a short-term period – e.g., between solution preparation and sterilization of the end-staged packaged product - an environment that does not facilitate the growth of harmful or undesirable microorganisms.
  • undesirable microorganisms include Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Bacillus subtilis and Aspergillus brasiliensis.
  • the packaging solutions should be gentle to the eye since at least some of the packaging solution will, most likely, remain on a contact lens once it is removed from the packaging solution and placed directly on (i.e., by direct application to) the eye.
  • the contact lens (or other ophthalmic device) packaging solution should also be compatible with the materials forming the contact lens (or other ophthalmic device) and the contact lens packaging.
  • a challenge in preparing packaging solutions for ophthalmic devices is formulating solutions which do not negatively affect eye comfort or the solution’s compatibility with the material(s) forming the ophthalmic device.
  • FIGURES Figure 1 is reproduction of “Influence of concentration of phosphate on NaCl effect on phosphate pH” illustration from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol.
  • the present invention relates to a sealed ophthalmologic product or kit, comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a phosphate compound buffer; ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; and 2 Docket No. VTN6162WOPCT1 iii. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition.
  • the present invention also relates to a method of inhibiting the growth of microorganisms in a composition from preparation of the composition to sterilization of the composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound buffer; and ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d. sealing the container of step c.; e.
  • the present invention further relates to a method of packaging and sterilizing a composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound buffer; and ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; b.
  • composition placing the composition in a container; 3 Docket No. VTN6162WOPCT1 c. sealing the container of step b.; d. sterilizing the container of the c. optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
  • peroxides e.g., hydrogen peroxide
  • sources of peroxides, persulfates carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
  • the present invention also relates to methods of making and using the disclosed compositions.
  • the present invention relates to compositions comprising one or more chelants and one or more phosphate compound as an ophthalmologically acceptable carrier.
  • the compositions may be useful for storing or as a packaging solution for ophthalmic devices.
  • the present invention provides ophthalmic solutions comprising a transient microbial growth inhibiting compound that is bacteriostatic from the formulation of the composition through heat sterilization, such as autoclaving, but substantially or entirely neutralized during sterilization providing a non-preserved ophthalmic solution after sterilization.
  • the present invention further provided hermetically sealed contact lens packages comprising a contact lens and an ophthalmic solution of the present invention.
  • compositions may be useful for direct application to the eyes for an eye care benefit such as relieving eye discomfort.
  • compositions and methods of the present invention can comprise, consist of, or consist essentially of the steps, essential elements and limitations of the invention described herein, as well any of the additional or optional ingredients, components, or limitations described herein.
  • the term “comprising” (and its grammatical variations) as used herein is used in the inclusive sense of “having” or “including” and not in the exclusive sense of “consisting only of.”
  • the terms “a” and “the” as used herein are understood to encompass the plural as well as the singular. 4 Docket No. VTN6162WOPCT1 Unless otherwise indicated, all documents cited are incorporated herein by reference.
  • ophthalmically acceptable and/or compatible means the composition or component(s) is pharmaceutically acceptable and is not or substantially is not, detrimental, negative, or harmful to any part of the eye (or surrounding tissues) or the other ingredients (including actives) in the composition itself.
  • water soluble means that the components, either alone or in combination with other components, do not form precipitates or gel particles visible to the human eye at the concentrations selected and across the temperatures and pH regimes common for manufacturing, sterilizing and storing the ophthalmic solution.
  • cationic preservatives means net positively charged compounds having antimicrobial properties and include, without limitation thereto, one or more of polymyxin B sulfate, quaternary ammonium compounds, poly(quaternary ammonium) compounds, benzalkonium chloride, cetylpridinium chloride, benzethonium chloride, cetyltrimethyl ammonium bromide, chlorhexidine, poly(hexamethylene biguanide), and mixtures thereof.
  • Poly(quaternary ammonium) compounds are compounds that are positively charged surface active agents (i.e., cationic surfactants ) which act to compromise the cell walls and membranes , and examples include BUSAN 77, ONAMERM, MIRAPOLA15, IONENES A, 5 Docket No. VTN6162WOPCT1 POLYQUATERNIUM 11, POLYQUATER NIUM 7, BRADOSOL, AND POLYQUAT D-17- 1742.
  • the term “effective to inhibit”, as used herein means an amount which causes an inhibition in the growth of microorganisms.
  • the term “lidstock”, as used herein means, a flexible film or sheet which is heat sealed to the concave side of the plastic blister packaging to form a sealed cavity.
  • Lidstock is generally multilayered and comprises a support layer and a peelable seal layer.
  • the lidstock may further comprise additional layers including print layers, lamination layers, foil layers and combinations thereof and the like.
  • the term “inhibition of growth of microorganisms” in the composition occurs where, and means that, there is a less than a 0.5 log, less than 0.3 log, less than 0.2 log, increase, or no increase in the count of any microorganism present in the composition after 1 day, 2 days, 3 days, 5 days, 7 days, 8 days, 10 days, 13 days, 14 days, 15 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention.
  • hydrogels means polymeric networks that swell in water or aqueous solutions, typically absorbing at least 10 weight percent water.
  • Silicone hydrogels are hydrogels that are made from at least one silicone-containing component with at least one hydrophilic component. Hydrophilic components may also include non-reactive polymers.
  • chlorous acid compounds means compounds containing a chlorous acid or ophthalmically compatible salts thereof are ophthalmically.
  • the chlorous acid compound may be an anhydride or a hydrate.
  • the salts of chlorous acid may be a mono or a double salt.
  • chlorous acid compounds examples include (selected from or selected from the group consisting of), but are not limited to, chlorous acid; an alkali metal salt of chlorous acid including lithium chlorite, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, barium chlorite, or barium chlorite dihydrate and the like; an earth metal salt of chlorous acid such as aluminum chlorite; a zinc-family salt of chlorous acid such as zinc chlorite dihydrate; a 6 Docket No.
  • VTN6162WOPCT1 transitional metal salt of chlorous acid such as copper chlorite (II), copper chlorite (III), silver chlorite, nickel chlorite dihydrate or manganese chlorite; ammonium chlorite; a quaternary ammonium salt of chlorous acid such as tetramethylammonium chlorite; a quaternary phosphonium salt of chlorous acid such as (2,4-dinitrophenyl) triethylphosphonium chlorite; an amine salt of chlorous acid such as a methyl amine salt of chlorous acid, a tripropyl amine salt of chlorous acid, a hydrazine salt of chlorous acid, a pyridine salt of chlorous acid, a 4-methyl pyridine salt of chlorous acid, a 2,4-dimethyl pyridine salt of chlorous acid or a quinoline salt of chlorous acid; a double salt such as KClO2 ⁇ NaClO2, Cu (ClO2)2
  • chlorous acid compounds such as stabilized oxychloro complex, (Purite, Bio-Cide International Inc., Ok, USA) and/or stabilized chlorite peroxide (SOC - Oxyd Tubilux.) may also be avoided.
  • Salts of chlorous acid compounds include ophthalmically compatible salts including but not limited to, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, or aluminum chlorite, ammonium chlorite; a quaternary ammonium salt of chlorous acid such as tetramethylammonium chlorite; a quaternary phosphonium salt of chlorous acid such as (2,4-dinitrophenyl) triethylphosphonium chlorite; an amine salt of chlorous acid such as a methyl amine salt of chlorous acid, a tripropyl amine salt of chlorous acid, a pyridine salt of chlorous acid, a 4-methyl pyridine salt of chlorous acid, a 2,4-dimethyl pyridine salt of chlorous acid or a quinoline salt of chlorous acid and mixtures of any of the
  • Chlorite compounds include chlorite compounds and salts thereof, including (selected from or selected from the group consisting of), but are not limited to, water soluble alkali metal chlorites, water soluble alkaline metal chlorites and mixtures thereof. Specific examples of chlorite compounds that may be avoided include (selected from or selected from the group consisting of) potassium chlorite, sodium chlorite, calcium chlorite, magnesium chlorite and mixtures thereof. All percentages, parts and ratios are based upon the total weight of the composition of the present invention, unless otherwise specified. All such weights as they pertain to the listed 7 Docket No.
  • VTN6162WOPCT1 ingredients are based on the active level and, therefore, do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified. It has been surprisingly found that certain chelating agents, such as EDTA can provide bacteriostatic properties for inhibiting microbial growth in the compositions when used at concentrations between about 0.025 to about 0.075 wt% based upon the total weight of the composition upon formulation without the addition of other microbial growth inhibiting compounds such as chlorous acid compounds or peroxides.
  • EDTA can provide bacteriostatic properties for inhibiting microbial growth in the compositions when used at concentrations between about 0.025 to about 0.075 wt% based upon the total weight of the composition upon formulation without the addition of other microbial growth inhibiting compounds such as chlorous acid compounds or peroxides.
  • the bacteriostatic properties for inhibiting microbial growth may occur for and are in effect during a period of time, which may be from the preparation or manufacture of the compositions of the present invention up to the time of performing at least one sterilization method on the composition, which may be sterilization of the composition in a sealed package with at least one contact lens as described below.
  • the period of time period may be up to two weeks, during which the solution is stored in a sealed container at ambient temperature.
  • period of time as used in association with the bacteriostatic properties of the composition, it is meant up to or at least one day, two days, three days, four days, five days , six days, seven days eight days, ten days, twelve days, fourteen days, fifteen days, 18 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention.
  • the period of time may be up two weeks, during which the solution is stored in a sealed container at ambient temperature.
  • Buffers A variety of buffers may be used in the present invention, including one or more phosphate compound, sulfate compound, borate compound or organic acid buffer and mixtures thereof.
  • the buffer has the buffer capacity and is present in an amount effective to buffer the composition to a pH of from about 5.0 to a pH of about 8.0, from about 5.5 to about 8.0, or a pH or a pH about 6.0 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of greater than 7.2 (or about 7.2) to a pH of 7.5 (or about 7.5).
  • the buffer may be include a borate buffer.
  • Suitable borates include, but are not limited to, boric acid; pharmaceutically acceptable salts of boric acid, such as 8 Docket No. VTN6162WOPCT1 alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof.
  • borate buffers include boric acid, sodium borate decahydrate and mixtures thereof.
  • the borate compound can be present in the compositions at concentrations of from about 0.1%, preferably from about 0.2%, preferably from about 0.25%, w/v to less than or equal to 0.80% (or about 0.80%), preferably 0.7% (or about 0.7%), preferably 0.6% (or about 0.6%), preferably 0.5% (or about 0.5%), preferably 0.45% (or about 0.45%), preferably 0.4% (or about 0.4%), preferably 0.35% (or about 0.35%), preferably 0.3% (or about 0.3%), w/v, in each case, of the total composition.
  • Phosphate Compound The compositions of the present invention, at the time of mixing, comprise a phosphate compound.
  • phosphate shall refer to phosphoric acid, anions and/or salts of phosphoric acid and other pharmaceutically acceptable phosphates, or combinations thereof. Suitable phosphates may be incorporated as one or more monobasic phosphates, dibasic phosphates and the like. Examples of phosphate compounds useful in the compositions are those selected from pharmaceutically acceptable phosphate salts of alkali and/or alkaline earth metals.
  • the phosphate compound may include one or more of phytic acid (or salts thereof such as their potassium or sodium salts), sodium dibasic phosphate (Na2HPO4), sodium monobasic phosphate (NaH 2 PO 4 ), and potassium monobasic phosphate (KH 2 PO 4 ) salts.
  • phytic acid or salts thereof such as their potassium or sodium salts
  • Na2HPO4 sodium dibasic phosphate
  • NaH 2 PO 4 sodium monobasic phosphate
  • KH 2 PO 4 potassium monobasic phosphate
  • the phosphate compound may be present in an amount from 0.3wt% (or about 0.3%) to 0.9wt% (or about 0.9%), or from 0.4wt% (or about 0.4wt%) to 0.85wt% (or about 0.85wt%), or from 0.5wt% (or about 0.5wt%) to 0.8 wt% (or about 0.8wt%) or from 0.6 wt% (or about 0.6 wt%) to 0.75 wt% (or about 0.75wt%), based on the total composition upon formulation.
  • the phosphate compound may be a combination of salts of the dibasic phosphate anion (HPO 4 ) 2- and salts of the monobasic phosphate anion (H 2 PO 4 )- where the concentration, prior to sterilization of the composition, of the dibasic phosphate anion (HPO4) 2- is from about 0.700% to about 0.900% and the concentration, prior to sterilization of the composition, the monobasic phosphate anion (H2PO4)- is from 0.500% to about 0.710%, by 9 Docket No. VTN6162WOPCT1 total weight of the composition when present as the sodium salt mono- and heptahydrates, respectively.
  • compositions of the present invention comprise an organic acid buffer wherein the organic acid buffer is added to compositions of the present invention in its undissociated form or as the metal salt thereof.
  • organic acid buffer means an organic acid having two or more carboxylic acid groups.
  • Preferred organic acid buffers for use in the compositions of the present invention have a or pK 2 value in the range of 6 (or about 6) to 8 (or about 8), preferably 6 (or about 6 ) to 7 ( or about 7).
  • phytic acid or salts thereof such as their potassium or sodium salts.
  • Phytic acid has 12 replaceable protons, whereby six are strongly acidic (pKa approximately 1.5), three are weaker acidic (pKa between 5.7 and 7.6), and three are very weakly acidic (pKa >10.0) (Costello, A. J. R.; Glonek, T.; Myers, T. C., 1976: 31 P-nuclear magnetic resonance-pH titrations of myo-inositol hexaphosphate. Carbohydrate Research 46, 159–171). Mixtures of the above acids may also be used.
  • the organic acid buffer may be selected from phytic acid, mellitic acid, maleic acid and salts thereof (such the sodium or potassium salts of the organic acids) and mixtures thereof.
  • the organic acid buffer may be selected from maleic acid, its sodium or potassium salts and mixtures thereof.
  • the organic acid buffer may be selected from mellitic acid, its sodium or potassium salts and mixtures thereof.
  • the organic acid content (as sum of mono- and di-basic salts) of the present compositions is in the range of about 0.10% to about 0.4%, or about 0.18% to about 0.30%, or about 0.20% to about 0.28%, by weight the total weight of the composition upon formulation.
  • the organic acid buffer may be a combination of salts of the dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of the monobasic organic acid anion (monobasic sodium maleate) where the concentration, prior to sterilization of the composition, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration, prior to sterilization of the composition, the monobasic organic acid anion is from 0.005% to about 10 Docket No. VTN6162WOPCT1 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.
  • the dibasic organic acid anion e.g., dibasic sodium maleate monohydrate
  • monobasic organic acid anion monobasic sodium maleate
  • compositions of the present invention may also contain neutral salts (e.g., sodium chloride) to meet human physiologic osmolality requirements. It is well known that the presence of such neutral salts affects the pH of phosphate buffers. Increasing the concentration of neutral salts results in a negative shift in pH (i.e., resulting in more acidic environment). Without being limited by theory, it is believed that these departures from ideal behavior result from electrostatic interactions of the cations of the neutral and phosphate salts. This is illustrated in Figure 1 (reproduced from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol. Chem., LXXXII (3), 775-802, (1929)).
  • neutral salts e.g., sodium chloride
  • the neutral salt e.g., sodium chloride
  • the neutral salt is present at a concentration of from 0.62% (or about 0.62%) to 0.66% (or about 0.66%), or from 0.58% (or about 0.58%) to 0.75% (or about 0.75%, or from 0.10% (or about 0.10%) to 0.28% (or about 0.28%), or from 0.00% to 0.35% (or about 0.35%), by weight, of the composition of the present invention.
  • compositions of the present invention comprise monobasic phosphate anions (H 2 PO4)- and dibasic phosphate anions (HPO4) 2- at following ratios: Neutral salt (e.g., sodium Monobasic phosphate anions (H 2 PO 4 )-/ Dibasic chloride) Concentration (wt%) phosphate anions (HPO 4 ) 2- Ratio 0.45% to 1.20% 0:1 to 0.45:1 0.50% to 0.90% 0.02:1 to 0.44:1 0.55% to 0.85% 0.10:1 to 0.34:1 0.60% to 0.80% 0.12:1 to 0.30:1 0.65% to 0.75% 0.14:1 to 0.24:1 Chelating Agent
  • the compositions of the present invention comprise a chelating agent capable of providing the composition with bacteriostatic properties for inhibiting microbial growth during a period of time as described above.
  • Suitable chelating agents include, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof.
  • the chelant may comprise EDTA. It has been surprisingly found that when the chelating agent, for example, EDTA is used at relatively high concentrations of about 0.02 to about 0.075 wt% EDTA, about 0.025 to about 0.075 wt% EDTA, or about 0.05 to about 0.075 wt% EDTA, based upon the total composition upon formulation. Other microbial growth inhibiting compounds do not need to be added to the composition to prevent microbial growth between formulating the composition and sterilization.
  • compositions comprising the chelating agent may remain colorless or lightly colored, even after autoclaving, which can be determined visually or measured via known methods such as APHA color technique.
  • the solution after autoclaving may have a APHA color value of less than about 180, or less than about 40. 12 Docket No. VTN6162WOPCT1 An Ophthalmologically Acceptable Carrier
  • the compositions of the present invention comprise an ophthalmologically acceptable carrier.
  • the ophthalmologically acceptable carrier may be water or an aqueous excipient solution.
  • aqueous typically denotes a formulation wherein the excipient is at least about 50%, or at least about 75% or at least about 90% and up to about 95%, or about 99%, by weight, water.
  • the compositions of the present invention are free of oils or oily substances (e.g., medium-chain triglycerides, castor oil, flaxseed oil and the like or mixtures thereof).
  • oils or oily substances e.g., medium-chain triglycerides, castor oil, flaxseed oil and the like or mixtures thereof.
  • substantially free as used with respect to the oil or lipid compounds, means the present compositions contain less than 0.05%, or less than 0.025%, or less than 0.01%, or less than 0.005%, of such oils or oily components, by weight, based on the total composition.
  • the compositions are not multiphasic compositions such as oil in water emulsions.
  • the water is preferably distilled water.
  • the carrier is free of C1-4 alcohols such as methanol, ethanol, propanol, isopropanol, butanol, and the like which can sting, irritate, or otherwise cause discomfort to the eye.
  • the water may be present in the ophthalmologically acceptable carrier at concentrations of from about 96% to about 99.9%, or from about 98% to about 99.5%, or from about 99.0% to about 99.5%, by weight of the total composition.
  • the ophthalmologically acceptable carrier may be present at concentrations of from about 96% to about 99.5%, or from about 98% to about 99.5%, or from about 98.5% to about 99.2%, by weight of the total composition.
  • compositions may be sterile, namely such that the absence of microbial contaminants in the product prior to release or use are statistically demonstrated to the degree necessary for such products.
  • the compositions may be selected to have no or substantially no detrimental, negative, harmful effect on the contact lens being therein or on the eye (or on the region around the eye). 13 Docket No. VTN6162WOPCT1
  • the compositions according to the present invention are physiologically compatible with the eye and ophthalmic devices.
  • the composition should be “ophthalmologically safe” for use with an ophthalmic device such as a contact lens, meaning that a contact lens treated with the solution is generally suitable and safe for direct placement on or direct application to the eye without rinsing, that is, the solution is safe and comfortable for ophthalmic devices, of any frequency of application, wetted with the solution, including contact lenses of any wear frequency.
  • An ophthalmologically safe composition has a tonicity and pH that is compatible with the eye and includes materials, and amounts thereof, that are ophthalmologically compatible and non-cytotoxic according to ISO standards and U.S. Food & Drug Administration (FDA) regulations.
  • compositions of the present invention may be adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids, which is equivalent to a 0.9 percent solution of sodium chloride.
  • the compositions may be made substantially isotonic with physiological saline used alone or in combination with other tonicity agents such as dextrose, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the ophthalmic devices such as contact lenses may lose their desirable optical parameters.
  • excess saline may result in the formation of a hypertonic composition, which will cause stinging, and eye irritation.
  • the osmolality of the composition may be at least about 200 mOsm/kg to less than 500 mOsm/kg, or from about 200 to about 450 mOsm/kg, or from about 205 to about 380 mOsm/kg, or from about 210 to about 360 milliosmoles per kilogram (mOsm/kg), or from about 250 to about 350 mOsm/kg, or from about 270 to about 330 mOsm/kg, as measured using osmolality measurement method USP ⁇ 785> (current as of November, 2022).
  • the ophthalmic compositions will generally be formulated as sterile aqueous compositions or as non-sterile compositions which are subsequently sterilized.
  • suitable tonicity adjusting agents include (selected from or selected from the group consisting of), but are not limited to, sodium, potassium, calcium, zinc and magnesium chloride, alkali metal halides, dextrose, and the like and mixtures thereof. These agents may be used individually in amounts ranging from about 0.01 to about 2.5%, from about 0.2 to about 1.5%, by weight of the total composition. 14 Docket No. VTN6162WOPCT1
  • the tonicity adjusting agent may be sodium chloride which can be incorporated at concentrations of from about 0.4 to about 0.9%, from about 0.4 to about 0.7%, or from about 0.5% to about 0.6% by weight of the total composition.
  • the ophthalmologically acceptable carrier can contain one or more of the above- mentioned tonicity agents.
  • compositions of the present invention may have a pH of from about 5.0 to a pH of about 8.0, or a pH of from about 5.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of about 7.2 to a pH of about 7.4.
  • Compositions may have a pH matching the physiological pH of the human tissue to which the composition will contact or be directly applied.
  • the pH of the ophthalmic composition may be adjusted using acids and bases, such as mineral acids, such as, but not limited to hydrochloric acid and bases such as sodium hydroxide.
  • compositions of the present invention are also useful as packaging solutions for packaging of ophthalmic devices and for storing such ophthalmic devices.
  • the packaging solutions of the present invention may have a viscosity of less than about 5.2 cP at 25oC.
  • ophthalmic device refers to an object that resides in or on the eye. These devices can provide optical correction, cosmetic enhancement, light blocking (including UV, HEV, visible light and combinations thereof) glare reduction, therapeutic effect, including preventing the progression of myopia, wound healing, delivery of drugs or neutraceuticals, diagnostic evaluation or monitoring, or any combination thereof.
  • Ophthalmic devices include (selected from or selected from the group consisting of), but are not limited to, soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, punctual plugs, and optical inserts.
  • the ophthalmic device may be a contact lens.
  • Contact lenses (or “contacts”) are placed directly on the surface of the eyes (e.g., placed on the film of tears that covers the surface of the eyes).
  • Contact lenses include soft contact lens (e.g., conventional or silicone hydrogel), rigid contact lenses or hybrid contact lenses (e.g., with soft skirt or shell).
  • Soft contact lenses may be formed from hydrogels. Contact lenses useful with the compositions can be manufactured employing various conventional techniques, to yield a shaped article having the desired posterior and anterior lens surfaces.
  • Contact lens polymer materials useful for manufacturing suitable contact lenses include (selected from or selected from the group consisting of), but are not limited to, acofilcon A, alofilcon A, alphafilcon A, amifilcon A, aquafilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A,balilcon A, deltafilcon A, delefilcon, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, fanfilcon A, focofilcon A, galyfilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lene
  • the contact lenses may be manufactured using polymer materials selected from (or selected from the group consisting of) comfilcon, etafilcon A, galyfilcon A, senofilcon A, senofilcon C, nelfilcon A, hilafilcon, samfilcon, serafilcon, tetrafilcon A, vasurfilcon, vifilcon, and polymacon.
  • Conventional hydrogel contact lenses do not contain silicone containing components, and generally have higher water content, lower oxygen permeability and moduli than silicone hydrogels.
  • hydrogels are prepared from monomeric mixtures predominantly containing hydrophilic monomers, such as 2-hydroxyethyl methacrylate (“HEMA”), N-vinyl pyrrolidone (“NVP”) or polyvinyl alcohols.
  • hydrophilic monomers such as 2-hydroxyethyl methacrylate (“HEMA”), N-vinyl pyrrolidone (“NVP”) or polyvinyl alcohols.
  • HEMA 2-hydroxyethyl methacrylate
  • NDP N-vinyl pyrrolidone
  • United States Patents Nos.4,436,887, 4,495,313, 4,889,664, 5,006,622, 5,039,459, 5,236,969, 5,270,418, 5,298,533, 5,824,719, 6,420,453, 6,423,761, 6,767,979, 7,934,830, 8,138,290, and 8,389,597 disclose the formation of conventional hydrogels.
  • Conventional hydrogels may be ionic or non-ionic and include (selected from or selected from the group consisting of) polymacon, etafilcon, genfilcon, hilafilcon, nesofilcon, nelfilcon, ocufilcon, omafilcon, lenefilcon and the like.
  • the oxygen permeability of these conventional hydrogel materials is typically below 20-30 barrers. 16 Docket No.
  • Silicon hydrogel formulations may include aquafilcon, balafilcon, samfilcon, lotrafilcon A and B, delefilcon, galyfilcon, senofilcon A, B and C, narafilcon, comfilcon, formofilcon, riofilcon, fanfilcon, stenfilcon, somofilcon, serafilcon, kalifilcon, verofilcon and the like.
  • “Silicone hydrogels” refer to polymeric networks made from at least one hydrophilic component and at least one silicone-containing component.
  • hydrophilic components examples include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinyl lactams, N-vinyl amides, N-vinyl imides, N- vinyl ureas, O-vinyl carbamates, O-vinyl carbonates, other hydrophilic vinyl compounds, and mixtures thereof.
  • Non-limiting examples of hydrophilic components include N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP), N-vinyl acetamide (NVA), N-vinyl-N-methylacetamide (VMA), and mixtures thereof. Silicone- containing components are well known and have been extensively described in the patent literature.
  • the silicone-containing component may comprise at least one polymerizable group (e.g., a (meth)acrylate, a styryl, a vinyl ether, a (meth)acrylamide, an N- vinyl lactam, an N-vinylamide, an O-vinylcarbamate, an O-vinylcarbonate, a vinyl group, or mixtures of the foregoing), at least one siloxane group, and one or more linking groups (which may be a bond) connecting the polymerizable group(s) to the siloxane group(s).
  • a polymerizable group e.g., a (meth)acrylate, a styryl, a vinyl ether, a (meth)acrylamide, an N- vinyl lactam, an N-vinylamide, an O-vinylcarbamate, an O-vinylcarbonate, a vinyl group, or mixtures of the foregoing
  • siloxane group e.g.,
  • the silicone- containing components may, for instance, contain from 1 to 220 siloxane repeat units, from 3 to 100, from 3 to 40, or from 3 to 20 siloxane repeat units.
  • the silicone-containing component may also contain at least one fluorine atom.
  • the ophthalmic devices may also include a polymeric wetting agent, which may be incorporated into the ophthalmic device in a number of ways including, but not limited to, as a non-reactive polymer and become entrapped in the hydrogel upon polymerization forming a semi-interpenetrating network, may be polymerized (with or without crosslinking) in a preformed contact lens to form a fully or semi-interpenetrating network respectively or may be added to the packaging solution of the present invention and up-taken into the contact lens during sterilization Examples of these are disclosed in 6,367,929, US10,935,695, US8,053,539, US10,371,865, US10,370,476, US6,822,016, US7,
  • the polymeric wetting agent may be polymerizable, for example as polyamide macromers or prepolymers, and in this case, are covalently incorporated into the 17 Docket No. VTN6162WOPCT1 silicone hydrogels. Mixtures of polymerizable and non-polymerizable polyamides may also be used.
  • suitable wetting agents include cyclic and linear polyamides, and specific examples include polyvinylpyrrolidone (PVP), polyvinylmethyacetamide (PVMA), polydimethylacrylamide (PDMA), polyvinylacetamide (PNVA), poly(hydroxyethyl(meth)acrylamide), polyacrylamide, and copolymers and mixtures thereof.
  • the polymeric wetting agent may be PVP, a mixture of PVP (e.g., PVP K90) and PVMA (e.g., having a Mw of about 570 KDa).
  • PVP polyvinyl
  • PVMA polyvinyl acrylate copolymer
  • the polyamides When the polyamides are incorporated into the reactive monomer mixture they may have a weight average molecular weight of at least 100,000 daltons; greater than about 150,000; between about 150,000 to about 2,000,000 daltons; between about 300,000 to about 1,800,000 daltons. Higher molecular weight polyamides may be used if they are compatible with the reactive monomer mixture.
  • the hydrogel or silicone hydrogel formulations may also contain additional components such as, but not limited to, diluents, initiators, light absorbing compounds, including UV, HEV or visible light absorbers, photochromic compounds, pharmaceuticals, nutraceuticals, antimicrobial substances, tints, pigments, copolymerizable dyes, nonpolymerizable dyes, release agents, and combinations thereof.
  • Silicone hydrogel lenses may contain a coating, and the coating may be the same or different material from the substrate. Silicone hydrogels may have moduli in the range of 60-200, 60-150 or 80 -130 psi, water contents in the range of 20 to 60% and contact angles less than about 100 ⁇ , less than about 80 ⁇ , and less than about 60 ⁇ .
  • silicone hydrogels examples include acquafilcon, asmofilcon, balafilcon, comfilcon, delefilcon, enfilcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, lehfilcon, kalifilcon, narafilcon, riofilcon, samfilcon, senofilcon, serafilcon, somofilcon, stenfilcon, unifilcon, and verofilcon including all of their variants, as well as silicone hydrogels as prepared in US Patent Nos.4,659,782, 4,659,783, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,998,498, 6,087,415, 5,760,100, 5,776,999, 5,789,461, 5,849,811, 5,965,631, 6,367,929, 6,822,016, 6,867,245, 6,943,203, 7,247,692, 7,249,848, 7,553,8
  • the contact lens polymer material may be a silicone hydrogel polymer.
  • the silicone hydrogel may be selected from (or selected from the group consisting of) acquafilcon, asmofilcon, balafilcon A, comfilcon, delefilcon, enfilcon, fanfilcon, galyfilcon, lotrafilcon, senofilcon, samfilcon, somofilcon, stenfilcon, riofilcon, lehfilcon, kalifilcon, serafilcon, unifilcon, verofilcon.
  • compositions may also be useful for direct application to eye as a wetting or rewetting eye drop for providing relief to eye discomfort (e.g., burning sensations relating to the eye or general eye irritation).
  • eye discomfort e.g., burning sensations relating to the eye or general eye irritation.
  • the compositions of the present invention are not further mixed with another or separate composition(s) prior to direct application to the eye or for storing of (or as packaging solution for) ophthalmic devices (e.g., contacts) – namely the compositions of the present invention (or products thereof) are not in the form of 2- or multi- compositions or products.
  • compositions described herein may, at the time of mixing, be free of or substantially free of boric acid, borates, non-chlorous acid preservatives (especially cationic preservatives), peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, glycerin, polyoxyethylene-castor oil and/or derivatives thereof.
  • peroxides e.g., hydrogen peroxide
  • sources of peroxides e.g., peroxide
  • persulfates e.g., hydrogen peroxide
  • glycerin e.g., polyoxyethylene-castor oil and/or derivatives thereof.
  • borate refers to salts of boric acid and other pharmaceutically acceptable borates, or combinations thereof.
  • Suitable borates include, but are not limited to, boric acid; pharmaceutically acceptable salts, such as alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof.
  • pharmaceutically acceptable salts such as alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof.
  • alkaline metal salts such as sodium borate, potassium borate
  • alkaline earth metal salts such as calcium borate, magnesium borate
  • transition metal salts such as manganese borate
  • non-chlorous acid preservative means compounds, which are not chlorous acid compounds, but have antimicrobial properties.
  • preservatives include, but are not limited to, 4-chlorocresol, 4-chloroxylenol, benzalkonium, benzalkonium chloride (BAK), benzoic acid, benzyl alcohol, chlorhexidine, chlorobutanol, imidurea, m-cresol, methylparaben, phenols 0.5%, phenoxyethanol, sorbate, propionic acid, propylparaben, sodium benzoate, sorbic acid, thimerosol, polyquaternium compounds (such as polyquarternium-42 and polyquarternium-1), biguanide compounds (e.g., polyhexamethylene biguanide or polyaminopropyl biguanide).
  • BAK 4-chlorocresol, 4-chloroxylenol, benzalkonium, benzalkonium chloride
  • benzoic acid benzyl alcohol, chlorhexidine, chlorobutanol, imidurea, m-cresol, methylparaben,
  • Non-chlorous acid preservatives can be irritating to eye and/or cause allergic reactions, undesirably affecting consumers’ use of the eye care compositions or contact lens which contain (on its surface) such non-chlorous acid preservative due to the storage of the contact lens with such compounds.
  • the term “sources of peroxides”, means a compound or material that releases (or can release peroxide or hydrogen peroxide) in aqueous solution and includes, but are not limited to, barium peroxide, sodium peroxide, zinc peroxide, magnesium peroxide, calcium peroxide, strontium peroxide, lithium peroxide, butanone peroxide, cyclohexanone peroxide, benzoyl peroxide, urea hydrogen peroxide (carbamide peroxide, carbamide perhydrate, or percarbamide), percarbonates such as calcium percarbonate or magnesium percarbonate, tert- butylhydroperoxide, perborate salts such as sodium perborate, peroxy acids such as methyl ethyl ketone peroxide, mixtures thereof and derivatives.
  • Peroxides e.g., hydrogen peroxide
  • sources of peroxides can be harsh and irritating to eye and can undesirably affect consumers’ use of contact lens which contain (on its surface) the peroxides (e.g., hydrogen peroxide) and/or sources of peroxides due to the storage of the contact lens with such compounds.
  • the term "persulfates" means persulfate anions or salts of such persulfates and other pharmaceutically acceptable persulfates, or combinations thereof.
  • Suitable persulfates include, but are not limited to, sodium peroxymonosulfate, potassium peroxymonosulfate, sodium persulfate , ammonium persulfate potassium persulfate and mixtures thereof.
  • Persulfates can be harsh and irritating to eye and can undesirably affect consumers’ use of contact lens which contain (on its surface) the persulfates due to the storage of the contact lens with such compounds.
  • Humectants and/or demulcents such as carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum tragacanth), glycerin, polyoxyethylene-castor oil and/or derivatives thereof are well known thickening agents which, when present on surface of contact lenses, can undesirably affect consumers’ vision through contact lens, causing blurring or otherwise reducing vision clarity by either interacting with the surface of the contact lens or slowly diffusing from the tear fluid trapped between the eye-facing side of the contact lens and the corneal surface. Though the latter effect is generally temporary, dissipating within several minutes post insertion with trapped fluid being cleared by repetitive blinking, such visual impairing effects may be undesirable.
  • carboxy vinyl polymers e.g., carbomers
  • natural gums e.g., guar gum, gum tragacanth
  • glycerin polyoxyethylene-castor oil and/or derivatives thereof
  • substantially free as related to compounds selected from boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum 21 Docket No.
  • peroxides e.g., hydrogen peroxide
  • sources of peroxides e.g., persulfates
  • carboxy vinyl polymers e.g., carbomers
  • natural gums e.g., guar gum, gum 21 Docket No.
  • VTN6162WOPCT1 tragacanth)glycerin, polyoxyethylene-castor oil and/or derivatives means that such compounds are present in the compositions of the present invention as impurities which are not intentionally added or are at a concentration of less than 2% (or about 2%), or less than 1.5% (or about 1.5%), or less than 1% (or about 1%), or less than 0.5% (or about 0.5%), or less than 0.1% (or about 0.1%), or less than 0.05% (or about 0.05%), or less than 0.01% (or about 0.01%), or less than 0.005% (or about 0.005%) by weight of the total composition.
  • the compositions of the present invention may be free of such compounds.
  • contact lenses can be immersed in a composition of the present invention and stored in a suitable packaging container, in certain embodiments, a packaging container for single contact lens unit.
  • a packaging container for the storage of a contact lens includes at least a sealing layer sealing the container containing an unused contact lens immersed in the composition of the present invention.
  • the sealed container may be hermetically sealed packaging container and may have any form that creates a sealed space to contain the composition and contact lens.
  • the hermetically sealed packaging container may have any suitable form include sealed packets formed from two sheets of plastic, metal or multilayer structures or a blister pack in which a base with a concave well containing a contact lens is covered by a metal, plastic or laminate sheet adapted for peeling in order to open the blister-pack.
  • the sealed container may be formed from any suitable, generally inert packaging material providing a reasonable degree of protection to the lens.
  • the packaging material may be formed of plastic material such as polypropylene, polysulfone (PSU), polyethersulfone (PESU), polycarbonate (PC), polyetherimide (PEI), polyamides, including nylons, polyolefins including polypropylene, polymethylpentene, (PMP), and olefin co-polymers, including COPs (Cyclic Olefin Polymer) and COCs,(Cyclic Olefin Co-polymers), acrylics, rubbers, urethanes, fluorocarbons, polyoxymethylene, polyvinylchloride (PVC), polyphenylsulfide (PPS), polycarbonate copolymers, polyvinylidene fluoride (PVDF), and the like and copolymers and blends of the foregoing.
  • plastic material such as polypropylene, polys
  • Blends include polybutylene terephthalate polyester blends, including PBT and PC blends, PC/polyester blends, and polypropylene blended with COPs or COCs.
  • the plastic material may be selected from polypropylene, COPs (Cyclic Olefin Polymer) and COCs, (Cyclic Olefin Co-polymers) and blends thereof. 22 Docket No.
  • any water soluble, demulcent (or demulcent like – e.g., having demulcent properties such as viscosity increasing capabilities) polymer may also be employed in the composition of this invention provided that it has no (or no substantial) detrimental effect on the contact lens being stored or on the wearer of the contact lens (e.g., blurring or otherwise reducing vision clarity) at the concentrations used in the composition of the present invention or on the eye (or on the region around the eye).
  • Particularly useful components are those, which are water soluble, for example, soluble at the concentrations used in the presently useful liquid aqueous media.
  • Suitable water soluble demulcent polymers include, but are not limited to, demulcent polymers, such as block copolymer surfactants (e.g., block copolymers of polyethyleneoxide (PEO) and polypropyleneoxide (PPO)); polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers such as polyethylene glycols (e.g., polyethylene glycol 300, polyethylene glycol 400) and polyethylene oxides; hyaluronic acid, and hyaluronic acid derivatives such as sodium hyaluronate) ; chitosan; polysorbates such as polysorbate 80, polysorbate 60 and polysorbate 40); dextrans such as dextran 70; cellulosic derivatives such as carboxy methyl cellulose methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and methyl ethyl cellulose; acyclic polyamides such as those having a weight average molecular weight of
  • the block copolymers of PEO and PPO include poloxamers and poloxamines, including those disclosed in US6,440,366, herein incorporated by reference in its entirety.
  • the water-soluble demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof.
  • Water-soluble demulcent polymers may have molecular weights in excess of 100,000. When propylene glycol and/or 1,3-propanediol are used as water-soluble demulcent polymers, they may have molecular weights lower than 100,000.
  • any water-soluble polymer when used in the packaging solutions of the present invention, it may be included and present in amounts up to about 0.5, 1 or 2 weight %, or between about 0.001 and about 2%, or between about 0.005 and about 1 weight %, or between 23 Docket No. VTN6162WOPCT1 about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition.
  • any water soluble polymer when used in the direct application eye care formulation, such as an eye drop of the present invention, it may be included and present in amounts up to about 2, 5 or 10 weight %, or between about 0.001 and about 10 weight %, or between about 0.005 and about 2 weight % , or between about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 2 weight%, all based upon the weight of total composition.
  • the water-soluble demulcent polymer aids in preventing the ophthalmic device from sticking to the packaging container and may enhance the initial (and/or extended) comfort of the contact lens, packaged in the composition, when placed on the eye after removal from the packaging container.
  • the demulcent polymer may be a cellulosic derivative.
  • the cellulosic derivative may be present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition of the present invention.
  • Various other materials may be included with the compositions described herein. In the case of compositions of the present invention for direct application to the eye, surfactants may be included.
  • Surfactants suitable for such use include, but are not limited to, ionic and nonionic surfactants (though nonionic surfactants are preferred), RLM 100, POE 20 cetylstearyl ethers such as Procol® CS20, poloxamer block copolymers (such as Pluronic® F68, and block copolymers such as poly(oxyethylene)-poly(oxybutylene) compounds set forth in US2008/0138310 (which publication is herein incorporated by reference).
  • the poly(oxyethylene)-poly(oxybutylene) block copolymer may have the formula (EO)m(BO)n, wherein EO is oxyethylene and BO is oxybutylene, and wherein m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000, as disclosed in US8,318,144; m may also be 10 and n may be 5.
  • Surfactants may be present at concentrations of from about 0.01 to about 3%, or from about 0.01 to about 1%, or from about 0.02 to about 0.5%, or from about 0.02 to about 0.1%, by weight of the total composition of the present invention. It should be appreciated that some of 24 Docket No.
  • VTN6162WOPCT1 the components may perform more than one function, for example, some demulcents may also function as surfactants (e.g., PEO-PPO and PEO-PBO block copolymers). If desired, one or more additional components may be, optionally, included in the composition. Such optional component(s) are chosen to impart or provide at least one beneficial or desired property to the composition.
  • Such additional, but optional, components may be selected from components that are conventionally used in ophthalmic device care compositions
  • optional components include (or, are selected from or selected from the group consisting of) cleaning agents (for example in direct application eye drops or cleaning [or eye care solution]), wetting agents, nutrient agents, therapeutic agent, sequestering agents, viscosity builders, contact lens conditioning agents, antioxidants, and the like and mixtures thereof.
  • cleaning agents for example in direct application eye drops or cleaning [or eye care solution]
  • wetting agents for example in direct application eye drops or cleaning [or eye care solution]
  • nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
  • wetting agents for example in direct application eye drops or cleaning [or eye care solution]
  • nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
  • wetting agents for example in direct application eye drops or cleaning [or eye care solution]
  • nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
  • wetting agents for example
  • the ophthalmic solution comprises a phosphate buffer, about 0.02 to about 0.075 wt% EDTA, about 0.025 to about 0.075 wt% EDTA or about 0.05 to about 0.075 wt% EDTA, about 0.005 to about 0.01 wt% methyl ethyl cellulose and optionally up to about 1, about 1.5 or about 2 wt% PVP K30, K60 or K90, or K60, all by weight of the ophthalmic solution as formulated, prior to autoclaving.
  • the ranges may be combined in any permutation.
  • the ophthalmic solution may be used as a packaging solution with contact lenses, including silicone hydrogel contact lenses, comprising PVP.
  • All components in the ophthalmic solution of the present invention should be water- soluble.
  • One or more therapeutic agent may also be incorporated into the ophthalmic solution.
  • a wide variety of therapeutic agents may be used, so long as the selected active agent is inert in the presence of chelant generally.
  • Suitable therapeutic agents include those that treat or target any part of the ocular environment, including the anterior and posterior sections of the eye and include pharmaceutical agents, vitamins, nutraceuticals combinations thereof and the like. 25 Docket No.
  • Suitable classes of active agents include antihistamines, antibiotics, glaucoma medication, carbonic anhydrase inhibitors, anti-viral agents, anti-inflammatory agents, non- steroid anti-inflammatory drugs, antifungal drugs, anesthetic agents, miotics, mydriatics, immunosuppressive agents, antiparasitic drugs, anti-protozoal drugs, combinations thereof and the like.
  • active agents When active agents are included, they are included in an amount sufficient to produce the desired therapeutic result (a “therapeutically effective amount”).
  • Useful optional sequestering agents include, but are not limited to, citric acid, sodium citrate and the like and mixtures thereof.
  • the method of packaging and storing a contact lens comprises immersing the device in the compositions described above in a suitable container.
  • the method may include immersing the device in the composition prior to delivery to the customer/wearer, directly following manufacture of the contact lens.
  • the incorporation and storing of the device in the compositions may occur at an intermediate point before delivery to the ultimate customer (wearer) but following manufacture and transportation of the device in a dry state, wherein the dry device is hydrated by immersing the device in the compositions. Consequently, a package for delivery to a customer may comprise a hermetically sealed container containing one or more unused devices (e.g., contact lenses) immersed in the compositions.
  • the steps for packaging the ophthalmic device in the composition of the present invention may include: (1) molding an ophthalmic device (e.g., contact lens) in a mold comprising at least a first and second mold portion, (2) removing the device from the mold portions and removal of unreacted monomer and processing agents, (3) introducing the composition and the device into the packaging (or container), and (4) sealing the packaging.
  • the method may also include the step of sterilizing the contents of the packaging. Sterilization may take place prior to, or most conveniently after, sealing of the container and may 26 Docket No. VTN6162WOPCT1 be performed by any suitable method known in the art, e.g., by autoclaving of the sealed container at temperatures of about 120° C.
  • the compositions of the present invention are sterilized by autoclave sterilization.
  • the packaging may be a plastic blister packaging (or package), including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization.
  • compositions of the present invention as described in following examples illustrate specific embodiments of compositions of the present invention but are not intended to be limiting thereof. Other modifications can be undertaken by the skilled artisan without departing from the spirit and scope of this invention.
  • Table 1 shows the formulations for compositions having a range of chlorite concentrations useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition was prepared using conventional mixing technology.
  • ⁇ Aspergillus brasiliensis ((Quanti-CultTM)) - ATCC 16404 (Remel Inc.)
  • BS Bacillus subtilis – subspecies spizizenii (Epower TM) - ATCC 6633 (Microbiologics®) 28 Docket No.
  • VTN6162WOPCT1 ⁇ (CA) Candida albicans (Epower TM) - ATCC 10231 (Microbiologics ® ) The test microorganisms were resuspended following manufacturers’ instructions and approximately 0.5mL aliquots were spread plated onto two separate tryptic soy agar (TSA) media and Sabouraud dextrose agar (SDA) plates. The TSA and SDA plates were incubated at 30-35oC and 20-25oC respectively, for 2-7 days.
  • TSA tryptic soy agar
  • SDA Sabouraud dextrose agar
  • test microorganism suspensions were diluted until their population counts could be estimated using a hemocytometer. A population count of approximately 1.0 x 10 7 cells/mL was targeted for each final test microorganism suspension.
  • an aliquot ranging from 2.5 ⁇ L to 100 ⁇ L) was inoculated into 20mL of each of the samples of the test compositions of Table 3 to obtain an average starting microorganism population count of approximately 7000 CFU/mL.
  • Each inoculated sample of the compositions of Table 11 containing the designated test microorganism was stored at room temperature and at Day 0, Day 1, Day 2, and Day 3 samples were pour-plated in duplicate (Day 0 only) or triplicate with either molten TSA or SDA containing chloramphenicol as required.
  • the aliquot volumes were bracketed to increase the chances of the pour plate count results to be within the 25 CFU – 300 CFU countable range.
  • yeast Candida albicans microbial counts dropped to 0 after 8 days at all EDTA concentrations evaluated.
  • the fungus Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii microbial counts showed slight to moderate decreases at the higher EDTA concentrations (0.05 and 0.075 wt%).
  • the 0.025wt% EDTA showed no growth for Bacillus subtilis – subspecies spizizenii.
  • the 0.025 wt% EDTA also showed no growth for Aspergillus brasiliensis (the slight increase reported in Table 2 is within detection limits).
  • Examples 1-4 show that elevated concentration of EDTA, about 0.025 to about 0.075 wt% or about 0.005 to 0.075wt%, maintain or reduce microbial growth of the composition.
  • a sealed ophthalmologic product or kit comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a buffer; ii. about 0.02 to about 0.075 wt% chelant; and iii. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition.
  • a method of inhibiting the growth of microorganisms in a composition for a period of time occurring from preparation of the composition to sterilization of the composition in sealed a container comprising the steps of: a. mixing a composition comprising: iii.
  • a buffer iv. about 0.02 to about 0.075 wt% chelant
  • VTN6162WOPCT1 optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
  • peroxides e.g., hydrogen peroxide
  • sources of peroxides, persulfates carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
  • the product, kit or method of embodiments 1-3 wherein the microbial growth inhibiting compounds are selected from chlorous acid compounds, peroxides and mixtures thereof. 6.
  • the buffer is selected from phosphate compounds, organic acid buffers and mixtures thereof. 7.
  • the buffer comprises at least one phosphate compound.
  • phosphate compound comprises a combination of salts of the dibasic phosphate anion (HPO 4 ) 2- and salts of the monobasic phosphate anion (H 2 PO 4 )-.
  • the product, kit or method of embodiment 7, wherein the phosphate compound is sodium dibasic phosphate (Na 2 HPO 4 ), sodium monobasic phosphate (NaH 2 PO 4 ) or a mixture thereof. Docket No. VTN6162WOPCT1 10.
  • chelant is selected from ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, or mixtures thereof. 12. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the chelant comprises ethylenediaminetetraacetic acid (EDTA). 13. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition further comprises a demulcent polymer. 14.
  • the demulcent polymer is selected from block copolymer surfactants; polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers; hyaluronic acid and hyaluronic acid derivatives; chitosan; polysorbates; dextrans; cellulosic derivatives; acyclic polyamides and mixtures thereof. 15.
  • the demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof. 16. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is methyl ethyl cellulose. 17.
  • the demulcent polymer is a cellulosic derivative present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition. 18.
  • the demulcent polymer is a water-soluble polymer present in amounts up to about 0.5, about 1 or about 2 weight %, or between about 0.001 and about 2%, between about 0.005 and about 1 weight %, between about 0.01 and about 0.5 Docket No.
  • VTN6162WOPCT1 weight % or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition. 19.
  • composition has a pH of from about 5.0 to a about 8.0, about 5.5 to about 8.0, about 6.0 to a about 8.0, from about 6.5 to about 8.0, or a pH of from about 6.5 to 7.5, or a pH of about 7.0 to about 7.5.
  • composition has a pH of from about 7.0 to about 7.5, or about 7.2 to about 7.4. 22.
  • composition is manufactured under sterile conditions or sterilized during and/or after the period of time.
  • composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 25.
  • VTN6162WOPCT1 preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
  • the container further comprises an ophthalmic device.
  • the ophthalmic device is a contact lens.
  • the contact lens is a conventional hydrogel contact lens or a silicone hydrogel contact lens.
  • 31. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization.
  • a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization.
  • the sterilization is by autoclave sterilization. 33.
  • the contact lens further comprises a water- soluble polymer entrapped therein.
  • the composition prior to placing the composition in a container, the composition is stored for a period of time during which time there is inhibition of growth of microorganisms.
  • the composition has a pH of from about 6.0 to a about 8.0, from about 6.5 to about 8.0, or a pH of from about 6.5 to 7.5, or a pH of about 7.0 to about 7.5. 36.
  • the product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the container is a plastic blister package, including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization. 39.
  • the reductant comprises EDTA in a concentration of about 0.025 to about 0.075 wt% based upon the total composition upon formulation.
  • the hydrogel contact lens is silicone hydrogel contact lens.
  • the contact lens is a hybrid contact lens.
  • the buffer comprises a borate buffer.
  • the buffer comprises at least one organic acid buffer. 44.
  • the product, kit or method of embodiment 43 wherein the organic acid buffer is a non- phosphate containing organic acid having two or more carboxylic acid groups.
  • the composition of embodiments 43-44 wherein the organic acid buffer is selected from phytic acid, mellitic acid, maleic acid and ophthalmically compatible salts thereof.
  • the composition of embodiments 43-45, wherein the organic acid buffer is selected from mellitic acid, maleic acid and salts thereof and mixtures thereof.
  • 47. The composition of embodiments 43-46, wherein the organic acid buffer is maleic acid, salts thereof and mixtures thereof.
  • 48. The composition of embodiments 43-47 wherein the organic acid buffer is selected from maleic acid, its sodium or potassium salts and mixtures thereof. 49.
  • composition of embodiments 43-48 wherein the organic acid buffer is selected from mellitic acid, its sodium or potassium salts and mixtures thereof. Docket No. VTN6162WOPCT1 50.
  • the composition of embodiments 43-49 wherein the organic acid buffer comprises salts of dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of monobasic organic acid anion (monobasic sodium maleate). 51.
  • the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.
  • the composition is free of boric acid and borates.
  • the organic acid buffer is a non-phosphate containing organic acid having two or more carboxylic acid groups.
  • composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from phytic acid, mellitic acid, maleic acid and ophthalmically compatible salts thereof. 55. The composition of any of the preceding embodiments and any succeeding embodiments, wherein the organic acid buffer is selected from mellitic acid, maleic acid and salts thereof and mixtures thereof. 56. The composition of any of the preceding embodiments and any succeeding embodiments, wherein the organic acid buffer is maleic acid, salts thereof and mixtures thereof. 57. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from maleic acid, its sodium or potassium salts and mixtures thereof. 58.
  • composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from mellitic acid, its sodium or potassium salts and mixtures thereof. 59.
  • the composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer comprises salts of dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of monobasic organic acid anion (monobasic sodium maleate).
  • VTN6162WOPCT1 The composition of any of the preceding embodiments and any succeeding embodiments wherein prior to sterilization of the composition the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.
  • the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Agronomy & Crop Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dentistry (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Eyeglasses (AREA)

Abstract

La présente invention concerne des compositions de soins oculaires, comprenant des solutions de conditionnement pour lentilles de contact contenant au moins un composé phosphate et un chélateur en une quantité efficace pour neutraliser la croissance de micro-organismes sans composés inhibiteurs de croissance microbienne supplémentaires. L'invention divulgue également des méthodes d'utilisation des compositions de la présente invention.
PCT/IB2023/062625 2022-12-21 2023-12-13 Compositions pour dispositifs ophtalmologiques WO2024134380A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263476553P 2022-12-21 2022-12-21
US202263476537P 2022-12-21 2022-12-21
US63/476,553 2022-12-21
US63/476,537 2022-12-21
US202363492288P 2023-03-27 2023-03-27
US63/492,288 2023-03-27

Publications (1)

Publication Number Publication Date
WO2024134380A1 true WO2024134380A1 (fr) 2024-06-27

Family

ID=89321480

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2023/062628 WO2024134381A1 (fr) 2022-12-21 2023-12-13 Compositions pour dispositifs ophtalmologiques
PCT/IB2023/062625 WO2024134380A1 (fr) 2022-12-21 2023-12-13 Compositions pour dispositifs ophtalmologiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/062628 WO2024134381A1 (fr) 2022-12-21 2023-12-13 Compositions pour dispositifs ophtalmologiques

Country Status (2)

Country Link
TW (2) TW202439973A (fr)
WO (2) WO2024134381A1 (fr)

Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408429A (en) 1963-09-11 1968-10-29 Ceskoslovenska Akademie Ved Method for centrifugal casting a contact lens
US3660545A (en) 1961-12-27 1972-05-02 Ceskoslovenska Akademie Ved Method of centrifugally casting thin edged corneal contact lenses
US4113224A (en) 1975-04-08 1978-09-12 Bausch & Lomb Incorporated Apparatus for forming optical lenses
US4197266A (en) 1974-05-06 1980-04-08 Bausch & Lomb Incorporated Method for forming optical lenses
US4436887A (en) 1981-11-12 1984-03-13 Bausch & Lomb Incorporated N-Vinyl lactam based biomedical devices
US4495313A (en) 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
US4659782A (en) 1984-07-05 1987-04-21 E. I. Du Pont De Nemours And Company Acrylic star polymers containing single-and multi-functional monomers in the core
US4889664A (en) 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US5006622A (en) 1987-04-02 1991-04-09 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5039459A (en) 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US5236969A (en) 1987-04-02 1993-08-17 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5244981A (en) 1990-04-10 1993-09-14 Permeable Technologies, Inc. Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment
US5270418A (en) 1987-04-02 1993-12-14 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5271875A (en) 1991-09-12 1993-12-21 Bausch & Lomb Incorporated Method for molding lenses
US5298533A (en) 1992-12-02 1994-03-29 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5314960A (en) 1990-04-10 1994-05-24 Permeable Technologies, Inc. Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment
US5371147A (en) 1990-10-11 1994-12-06 Permeable Technologies, Inc. Silicone-containing acrylic star polymers, block copolymers and macromonomers
US5760100A (en) 1994-09-06 1998-06-02 Ciba Vision Corporation Extended wear ophthalmic lens
US5776999A (en) 1994-09-06 1998-07-07 Ciba Vision Corporation Methods of using and screening extended wear ophthalmic lenses
US5824719A (en) 1995-06-07 1998-10-20 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5998498A (en) 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6367929B1 (en) 1998-03-02 2002-04-09 Johnson & Johnson Vision Care, Inc. Hydrogel with internal wetting agent
US6420453B1 (en) 1990-10-29 2002-07-16 Biocompatibles Limited Contact lens material
US6440366B1 (en) 1997-06-06 2002-08-27 Bausch & Lomb Incorporated Contact lens packing solutions
WO2003022321A2 (fr) 2001-09-10 2003-03-20 Johnson & Johnson Vision Care, Inc. Dispositifs biomedicaux contenant des agents humidifiants internes
US6767979B1 (en) 1998-12-11 2004-07-27 Biocompatibles Uk Limited Crosslinked polymers and refractive devices formed therefrom
US6822016B2 (en) 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
US6867245B2 (en) 1999-12-16 2005-03-15 Asahikasei Aime Co., Ltd. Long wearable soft contact lens
US6943203B2 (en) 1998-03-02 2005-09-13 Johnson & Johnson Vision Care, Inc. Soft contact lenses
US7247692B2 (en) 2004-09-30 2007-07-24 Johnson & Johnson Vision Care, Inc. Biomedical devices containing amphiphilic block copolymers
US7249848B2 (en) 2004-09-30 2007-07-31 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents
US7262232B2 (en) 2000-04-18 2007-08-28 Coopervision, Inc. Ophthalmic lenses and compositions and methods for producing same
WO2008061992A2 (fr) 2006-11-22 2008-05-29 Sauflon Cl Limited Lentille de contact
US20080138310A1 (en) 2006-12-11 2008-06-12 Alcon Manufacturing, Ltd. Use of PEO-PBO block copolymers in ophthalmic compositions
US7431152B2 (en) 2003-04-24 2008-10-07 Coopervision International Holding Company, Lp Hydrogel contact lenses and package systems and production methods for same
US7553880B2 (en) 1994-09-06 2009-06-30 Ciba Vision Corporation Extended wear ophthalmic lens
US20090220618A1 (en) * 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
US20090239954A1 (en) * 2008-03-19 2009-09-24 Collins Gary L Phosphate buffered ophthalmic solutions displaying improved efficacy
US20100086514A1 (en) * 2009-10-01 2010-04-08 Liu X Michael Contact Lens Care Solutions with a Low Molecular Weight Oligomer
US7786185B2 (en) 2004-03-05 2010-08-31 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising acyclic polyamides
US7841716B2 (en) 2005-02-14 2010-11-30 Johnson & Johnson Vision Care, Inc. Comfortable ophthalmic device and methods of its production
US7934830B2 (en) 2007-12-03 2011-05-03 Bausch & Lomb Incorporated High water content silicone hydrogels
US7956131B2 (en) 2004-09-30 2011-06-07 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US8053539B2 (en) 2006-06-30 2011-11-08 Johnson & Johnson Vision Care Inc. Siloxanyl materials for molded plastics
US8138290B2 (en) 2008-01-25 2012-03-20 Bausch & Lomb Incorporated High water content ophthalmic devices
US8399538B2 (en) 1998-03-02 2013-03-19 Johnson & Johnson Vision Care, Inc. Contact lenses
US8470906B2 (en) 2008-09-30 2013-06-25 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
US8487058B2 (en) 2011-02-28 2013-07-16 Coopervision International Holding Company, Lp Wettable silicone hydrogel contact lenses
US8507577B2 (en) 2006-10-31 2013-08-13 Johnson & Johnson Vision Care, Inc. Process for forming clear, wettable silicone hydrogel articles
US8937110B2 (en) 2011-12-23 2015-01-20 Johnson & Johnson Vision Care, Inc. Silicone hydrogels having a structure formed via controlled reaction kinetics
US8937111B2 (en) 2011-12-23 2015-01-20 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising desirable water content and oxygen permeability
US8940812B2 (en) 2012-01-17 2015-01-27 Johnson & Johnson Vision Care, Inc. Silicone polymers comprising sulfonic acid groups
US9057821B2 (en) 2009-10-12 2015-06-16 Sauflon Cl Limited Method of making a contact lens
US9056878B2 (en) 2006-09-29 2015-06-16 Johnson & Johnson Vision Care, Inc. Hydrolysis-resistant silicone compounds
US9125808B2 (en) 2011-12-23 2015-09-08 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US9140825B2 (en) 2011-12-23 2015-09-22 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US9156934B2 (en) 2011-12-23 2015-10-13 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising n-vinyl amides and hydroxyalkyl (meth)acrylates or (meth)acrylamides
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US9297928B2 (en) 2004-11-22 2016-03-29 Johnson & Johnson Vision Care, Inc. Ophthalmic compositions comprising polyether substituted polymers
US9297929B2 (en) 2012-05-25 2016-03-29 Johnson & Johnson Vision Care, Inc. Contact lenses comprising water soluble N-(2 hydroxyalkyl) (meth)acrylamide polymers or copolymers
US10371865B2 (en) 2016-07-06 2019-08-06 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising polyamides
US10370476B2 (en) 2016-07-06 2019-08-06 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising high levels of polyamides
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US20230037781A1 (en) 2021-06-30 2023-02-09 Johnson & Johnson Vision Care, Inc. Transition metal complexes as visible light absorbers

Patent Citations (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660545A (en) 1961-12-27 1972-05-02 Ceskoslovenska Akademie Ved Method of centrifugally casting thin edged corneal contact lenses
US3408429A (en) 1963-09-11 1968-10-29 Ceskoslovenska Akademie Ved Method for centrifugal casting a contact lens
US4197266A (en) 1974-05-06 1980-04-08 Bausch & Lomb Incorporated Method for forming optical lenses
US4113224A (en) 1975-04-08 1978-09-12 Bausch & Lomb Incorporated Apparatus for forming optical lenses
US4495313A (en) 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
US4436887A (en) 1981-11-12 1984-03-13 Bausch & Lomb Incorporated N-Vinyl lactam based biomedical devices
US4659782A (en) 1984-07-05 1987-04-21 E. I. Du Pont De Nemours And Company Acrylic star polymers containing single-and multi-functional monomers in the core
US4659783A (en) 1984-07-05 1987-04-21 E. I. Du Pont De Nemours And Company Acrylic star polymers containing multifunctional monomers in the core
US5236969A (en) 1987-04-02 1993-08-17 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5006622A (en) 1987-04-02 1991-04-09 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5270418A (en) 1987-04-02 1993-12-14 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5039459A (en) 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US4889664A (en) 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US5244981A (en) 1990-04-10 1993-09-14 Permeable Technologies, Inc. Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment
US5314960A (en) 1990-04-10 1994-05-24 Permeable Technologies, Inc. Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment
US5331067A (en) 1990-04-10 1994-07-19 Permeable Technologies, Inc. Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment
US5371147A (en) 1990-10-11 1994-12-06 Permeable Technologies, Inc. Silicone-containing acrylic star polymers, block copolymers and macromonomers
US6420453B1 (en) 1990-10-29 2002-07-16 Biocompatibles Limited Contact lens material
US6423761B1 (en) 1990-10-29 2002-07-23 Biocompatibles Limited Contact lens material
US5271875A (en) 1991-09-12 1993-12-21 Bausch & Lomb Incorporated Method for molding lenses
US5298533A (en) 1992-12-02 1994-03-29 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
US7553880B2 (en) 1994-09-06 2009-06-30 Ciba Vision Corporation Extended wear ophthalmic lens
US5849811A (en) 1994-09-06 1998-12-15 Ciba Vision Corporation Extended wear ophthalmic lens
US5965631A (en) 1994-09-06 1999-10-12 Ciba Vision Corporation Extended wear ophthalmic lens
US5760100A (en) 1994-09-06 1998-06-02 Ciba Vision Corporation Extended wear ophthalmic lens
US5776999A (en) 1994-09-06 1998-07-07 Ciba Vision Corporation Methods of using and screening extended wear ophthalmic lenses
US5849811B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corporatin Extended wear ophthalmic lens
US5789461A (en) 1994-09-06 1998-08-04 Ciba Vision Corporation Methods of forming an extended wear ophthalmic lens having a hydrophilic surface
US5776999B1 (en) 1994-09-06 2000-11-21 Ciba Vision Corp Methods of using and screening extended wear opthalmic lenses
US5789461B1 (en) 1994-09-06 2000-11-21 Ciba Vision Corp Methods of forming an extended wear ophthalmic lens having a hydrophilic surface
US5824719A (en) 1995-06-07 1998-10-20 Bausch & Lomb Incorporated Polymer compositions for contact lenses
US6440366B1 (en) 1997-06-06 2002-08-27 Bausch & Lomb Incorporated Contact lens packing solutions
US8399538B2 (en) 1998-03-02 2013-03-19 Johnson & Johnson Vision Care, Inc. Contact lenses
US6367929B1 (en) 1998-03-02 2002-04-09 Johnson & Johnson Vision Care, Inc. Hydrogel with internal wetting agent
US5998498A (en) 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US6943203B2 (en) 1998-03-02 2005-09-13 Johnson & Johnson Vision Care, Inc. Soft contact lenses
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6767979B1 (en) 1998-12-11 2004-07-27 Biocompatibles Uk Limited Crosslinked polymers and refractive devices formed therefrom
US6867245B2 (en) 1999-12-16 2005-03-15 Asahikasei Aime Co., Ltd. Long wearable soft contact lens
US8637621B2 (en) 1999-12-16 2014-01-28 Coopervision International Holding Company, Lp Long-wearable soft contact lens
US7262232B2 (en) 2000-04-18 2007-08-28 Coopervision, Inc. Ophthalmic lenses and compositions and methods for producing same
US7666921B2 (en) 2001-09-10 2010-02-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
US6822016B2 (en) 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
US8450387B2 (en) 2001-09-10 2013-05-28 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
WO2003022321A2 (fr) 2001-09-10 2003-03-20 Johnson & Johnson Vision Care, Inc. Dispositifs biomedicaux contenant des agents humidifiants internes
US7431152B2 (en) 2003-04-24 2008-10-07 Coopervision International Holding Company, Lp Hydrogel contact lenses and package systems and production methods for same
US7786185B2 (en) 2004-03-05 2010-08-31 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising acyclic polyamides
US8022158B2 (en) 2004-03-05 2011-09-20 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising acyclic polyamides
US7247692B2 (en) 2004-09-30 2007-07-24 Johnson & Johnson Vision Care, Inc. Biomedical devices containing amphiphilic block copolymers
US7249848B2 (en) 2004-09-30 2007-07-31 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents
US8273802B2 (en) 2004-09-30 2012-09-25 Johnson & Johnson Vision Care, Inc. Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents
US7956131B2 (en) 2004-09-30 2011-06-07 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US9297928B2 (en) 2004-11-22 2016-03-29 Johnson & Johnson Vision Care, Inc. Ophthalmic compositions comprising polyether substituted polymers
US7841716B2 (en) 2005-02-14 2010-11-30 Johnson & Johnson Vision Care, Inc. Comfortable ophthalmic device and methods of its production
US8053539B2 (en) 2006-06-30 2011-11-08 Johnson & Johnson Vision Care Inc. Siloxanyl materials for molded plastics
US9056878B2 (en) 2006-09-29 2015-06-16 Johnson & Johnson Vision Care, Inc. Hydrolysis-resistant silicone compounds
US8507577B2 (en) 2006-10-31 2013-08-13 Johnson & Johnson Vision Care, Inc. Process for forming clear, wettable silicone hydrogel articles
US8703891B2 (en) 2006-11-22 2014-04-22 Sauflon Cl Limited Contact lens
US20100048847A1 (en) 2006-11-22 2010-02-25 Sauflon Cl Limited Contact Lens
WO2008061992A2 (fr) 2006-11-22 2008-05-29 Sauflon Cl Limited Lentille de contact
US8318144B2 (en) 2006-12-11 2012-11-27 Alcon Research, Ltd. Use of PEO-PBO block copolymers in ophthalmic compositions
US20080138310A1 (en) 2006-12-11 2008-06-12 Alcon Manufacturing, Ltd. Use of PEO-PBO block copolymers in ophthalmic compositions
US7934830B2 (en) 2007-12-03 2011-05-03 Bausch & Lomb Incorporated High water content silicone hydrogels
US8389597B2 (en) 2008-01-25 2013-03-05 Bausch & Lomb Incorporated High water content ophthalmic devices
US8138290B2 (en) 2008-01-25 2012-03-20 Bausch & Lomb Incorporated High water content ophthalmic devices
US20090220618A1 (en) * 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
US20090239954A1 (en) * 2008-03-19 2009-09-24 Collins Gary L Phosphate buffered ophthalmic solutions displaying improved efficacy
US8470906B2 (en) 2008-09-30 2013-06-25 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
US9260544B2 (en) 2008-09-30 2016-02-16 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
US20100086514A1 (en) * 2009-10-01 2010-04-08 Liu X Michael Contact Lens Care Solutions with a Low Molecular Weight Oligomer
US9057821B2 (en) 2009-10-12 2015-06-16 Sauflon Cl Limited Method of making a contact lens
US8487058B2 (en) 2011-02-28 2013-07-16 Coopervision International Holding Company, Lp Wettable silicone hydrogel contact lenses
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
US9244197B2 (en) 2011-12-23 2016-01-26 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising desirable water content and oxygen permeability
US8937110B2 (en) 2011-12-23 2015-01-20 Johnson & Johnson Vision Care, Inc. Silicone hydrogels having a structure formed via controlled reaction kinetics
US9156934B2 (en) 2011-12-23 2015-10-13 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising n-vinyl amides and hydroxyalkyl (meth)acrylates or (meth)acrylamides
US9125808B2 (en) 2011-12-23 2015-09-08 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US9140825B2 (en) 2011-12-23 2015-09-22 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US8937111B2 (en) 2011-12-23 2015-01-20 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising desirable water content and oxygen permeability
US8940812B2 (en) 2012-01-17 2015-01-27 Johnson & Johnson Vision Care, Inc. Silicone polymers comprising sulfonic acid groups
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US9297929B2 (en) 2012-05-25 2016-03-29 Johnson & Johnson Vision Care, Inc. Contact lenses comprising water soluble N-(2 hydroxyalkyl) (meth)acrylamide polymers or copolymers
US10371865B2 (en) 2016-07-06 2019-08-06 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising polyamides
US10370476B2 (en) 2016-07-06 2019-08-06 Johnson & Johnson Vision Care, Inc. Silicone hydrogels comprising high levels of polyamides
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US20210109255A1 (en) 2018-03-02 2021-04-15 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of uv and high energy visible light
US20230037781A1 (en) 2021-06-30 2023-02-09 Johnson & Johnson Vision Care, Inc. Transition metal complexes as visible light absorbers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUDOUIN SEE CLABBE ALIANG HPAULY ABRIGNOLE-BAUDOUIN F: "Preservatives in eyedrops: the good, the bad and the ugly", PROG RETIN EYE RES., vol. 29, no. 4, July 2010 (2010-07-01), pages 312 - 34, XP055616054, DOI: 10.1016/j.preteyeres.2010.03.001
COSTELLO, A. J. R.GLONEK, T.MYERS, T. C.: "P-nuclear magnetic resonance-pH titrations of m o-inositol hexaphosphate", CARBOHYDRATE RESEARCH, vol. 46, 1976, pages 159 - 171, XP009124634, DOI: 10.1016/S0008-6215(00)84287-1
LAKSHMAN SUBBARAMAN: "Contact lens material properties that influence preservative uptake", CONTACT LENS UPDATE, 1 October 2013 (2013-10-01), Retrieved from the Internet <URL:https://contactlensupdate.com/2013/10/01/contact-lens-material-properties-that-influence-preservative-uptake/>
ROBINSON, H., W.: "The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures", J. BIOL. CHEM., no. 3, 1929, pages 775 - 802

Also Published As

Publication number Publication date
WO2024134381A1 (fr) 2024-06-27
TW202439973A (zh) 2024-10-16
TW202439971A (zh) 2024-10-16

Similar Documents

Publication Publication Date Title
US7247270B2 (en) Method and composition for reducing contact lens swelling
EP4288813B1 (fr) Lentille de contact à libération de ws12
JP2011515393A (ja) 改善された有効性を示すリン酸塩緩衝眼科用溶液
US7282178B2 (en) Composition and method for cleaning lipid deposits on contact lenses
JP6654340B2 (ja) コンタクトレンズ用組成物およびそれを用いたコンタクトレンズパッケージ
EP2936215B1 (fr) Lentilles de contact ophtalmiques antimicrobiennes
WO2024134380A1 (fr) Compositions pour dispositifs ophtalmologiques
WO2024134384A1 (fr) Compositions pour dispositifs ophtalmologiques
WO2024134383A1 (fr) Compositions pour dispositifs ophtalmologiques
AU2022200172B2 (en) Compositions for ophthalmologic devices
US20240159938A1 (en) Compositions for Ophthalmologic Devices
WO2024134382A1 (fr) Compositions pour dispositifs ophtalmologiques
NZ784167A (en) Compositions for ophthalmologic device
HK40077981A (en) Compositions for ophthalmologic devices
HK40074917A (en) Compositions for ophthalmologic devices
US20060067981A1 (en) Contact lens with improved biocidal activity and related methods and materials
HK1209491B (en) Antimicrobial ophthalmic contact lenses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23828499

Country of ref document: EP

Kind code of ref document: A1